Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma
de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-Oncology 2015, 18: 283-290. PMID: 26691210, PMCID: PMC4724186, DOI: 10.1093/neuonc/nov307.Peer-Reviewed Original ResearchConceptsTumor volumeDisease monitoringIsocitrate dehydrogenase (IDH) mutant gliomasProton magnetic resonance spectroscopyConsecutive glioma patientsMR imaging protocolMagnetic resonance spectroscopyCytoreductive therapyTumor levelsLarge tumorsTumor gradeSmall tumorsGlioma patientsGlioma imagingGlioma therapyClinical practiceClinical implicationsRoutine MRTumor cellularityTumor cellsIDH-mutant gliomasGliomasMetabolite RImaging protocolMitotic index